Sanofi has acquired all outstanding shares, warrants and convertible bonds of Ablynx, following the expiration of the squeeze-out procedure.
Acquisition
The squeeze-out period started in May this year (2018) after Sanofi acquired more than 95% of the outstanding shares of Ablynx upon settlement of the initial acceptance period of its tender offer and was set out in accordance with applicable Belgian and US law.
Once the squeeze-out period expired (12 June) other shares (2,893,201) and convertible bonds (8) of Ablynx were tendered. Any shares and convertible bonds that were not tendered in the squeeze-out are deemed as transferred to Sanofi by operation of law. As such the funds required for the payment of these are kept with the Bank for Official Deposits. Former owners of the shares or convertible bonds can receive €45 per share and €393,700.78 per convertible bond, they need to simply contact the Bank for Official Deposits.
All shares of Ablynx have now been delisted from the regulated market of Euronext Brussels, American Depositary Shares have been delisted from NASDAQ Global Select Market and convertible bonds have been delisted from the open market Frankfurt MTF.